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Introduction. Microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients is a poor prognostic factor after liver
transplantation and/or resection. Any correlation between MVI and segmental location of HCC has yet to be studied. Our aim
is to evaluate the segmental location of HCC and any correlation with the presence of MVI, portal vein thrombosis (PVT) in
explanted livers, and the recurrence of HCC after transplantation. Another objective of the study is to assess the treatment history
(ablation or transarterial chemoembolization (TACE)) and size of the tumor with respect to the risk of MVI. Methods. A single
center, retrospective chart review, including 98 HCC patients, aged 18 years and older who had liver transplantation in our institute
between 2012 and 2017. We reviewed the radiological images of the HCC tumors, the pathological findings of the explanted livers,
and the follow-up imaging after transplantation. Results. 98 patients with the diagnosis of HCC underwent liver transplantation
between 2012 and 2017.Themean age of the cohort was 63 ± 8.2. Males represented 75% and Caucasian race represented 75% of the
cohort.Themost common etiology of cirrhosis was chronic hepatitis C virus infection followed by alcohol abuse and nonalcoholic
steatohepatitis (NASH) with percentages of 50%, 23%, and 10%, respectively. Microvascular invasion was found in 16% of the
patients while PVT and the recurrence of HCC were found in 17% and 6 % of the cohort, respectively. MVI was found in 10 single
HCC and 6 multifocal HCC. Right lobe HCC had more MVI when compared to the left and multilobar HCC, with percentages of
11%, 2%, and 3%, respectively. Localization ofHCC in segment 8 was associatedwith the highest percentage ofMVIwhen compared
to all other segments. The risk of MVI in segment 8 HCC was 3.5 times higher than the risk from the other segments (p=0.002)
while no vascular invasion was found in segments 1, 3, and 5. The risk of vascular invasion in untreated HCC is 3 times the risk
in treated HCC (P=0.03). Conclusion. Our data indicate that the risk of microvascular invasion is highest in tumors localized to
segment 8. The size and number of HCC tumors were not associated with an increased risk of microvascular invasion.
1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide and is the second leading cause of
cancer-related deaths [1]. This results in over 600,00 deaths
annually and a significant socioeconomic burden in the
United States [2]. Furthermore, these numbers will continue
to rise as HCC is currently considered as the fastest growing
cause of cancer-related death in the United States with
expectations of consistent growth over the next two decades
[3, 4].
Even after potentially curative therapy with either hepatic
resection or liver transplantation, tumor recurrence remains
70% at 5 years [5]. Microvascular invasion (MVI) has been
identified as an independent predictor of tumor recurrence
[6–8]. However, unlike macrovascular invasion which can be
detected via radiological imaging, MVI is a histological diag-
nosis without universal diagnostic criteria [6]. Furthermore,
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the exact mechanism and implication of MVI for HCC is not
well characterized.
Considering the difficulties of MVI identification prior
to treatment and the strong effect on clinical outcomes,
it is critical to characterize MVI in HCC for optimal
management. Current approaches to characterize MVI have
been targeted towards identifying prognostic factors and
evaluation criteria, but none have attempted to associate the
Couinaud segment predominance for HCC lesions with MVI
[6, 9, 10]. Understanding the anatomical preferences and
behavior within the liver could provide important observa-
tional and management information. In our study, we aim
to identify whether HCC present in the various hepatic
segments correlated with MVI in those particular hepatic
segments.
2. Methods
2.1. Data Sources. We retrospectively reviewed the medical
records of all patients over the age of 18 with pathology
confirmed hepatocellular carcinoma who had a liver trans-
plantation between January 1, 2012, and December 31, 2017,
at the University of Massachusetts. By using the International
Classification of Diseases (ICD) codes of hepatocellular car-
cinoma and liver transplantation, wewere able to identify this
patient’s cohort. The study was approved by the Institutional
Review Board of the University of Massachusetts Medical
School and a HIPAA waiver of consent was granted given
the retrospective and deidentified nature of the review. The
chart of each patient was reviewed and the extracted data
included the general demographic features of the cohort; the
age, gender, and the race of the patients.
2.2. Patient Cohort. We performed a single center, retro-
spective chart review study of patients over the age of 18.
Eighty-nine patients met the following inclusion criteria: a
pathological finding of HCC in an explanted liver after liver
transplantation at the University of Massachusetts Medical
Center (UMMC). Postoperative recurrence of HCC was
identified radiographically.The presence of PVTwas assessed
during the pretransplant period. Exclusion criteria were
defined as loss to follow-up, liver biopsy, or liver transplant
that was done outside the UMMS, incomplete records, and
diagnoses other than hepatocellular carcinoma.
3. Results
Ninety-eight patients with a diagnosis of HCC underwent
liver transplantation between 2012 and 2017. Baseline char-
acteristics of patients are shown in Table 1. The mean age
of the cohort was 63 ± 8.2. Males represented 75% of the
cohort. Caucasian race represented 75% of the cohort. The
most common etiology of cirrhosis was chronic hepatitis C
virus infection followed by alcohol abuse and nonalcoholic
steatohepatitis (NASH) with percentages of 50%, 23%, and
10%, respectively. From comparisons of patient characteris-
tics according to the presence of MVI in the 98 explanted
livers, MVI was found in 16 specimens (16.3%) with 10 being
identified as single foci HCC and 6 as multifocal HCC. Portal
Table 1: Baseline characteristics of the study cohort.
Characteristics Number (%)
Age 63 +/- 8.2
Gender
Male 74(75%)
Female 24(25%)
Race
Caucasian 75 (75%)
African-American 4(4%)
MELD
HCV 50 (50%
HBV 9(9%)
Alcohol 23(23%)
NASH 10 (10%)
CTP A 24(24%)
CTP B 35 (35%)
CTP C 39 (39%)
Multifocal 46 (46%)
Single 52 (52%)
Segment 1 1 (1%)
Segment 2 4 (4%)
Segment 3 0 (0%)
Segment 4 5 (5%)
Segment 5 6 (4%)
Segment 6 6 (6%)
Segment 7 7 (7%)
Segment 8 18 (18%)
Undetermined 5 (5%)
Vascular Invasion 16 (16%)
Recurrence 6 (6%)
PVT 17 (17%)
vein thrombosis (PVT) was found in 17% of the cohort.
Postoperative recurrence of HCC within the 5-year period of
the study was found in 6% of the cohort (Table 1).
Further comparison of right and left lobe MVI showed a
right-sided predominance when compared to left and multi-
lobar HCC with percentages of 11%, 2%, and 3%, respectively
(Table 2). We studied the association of the segment-specific
location of the HCC and the presence of MVI which showed
that localization of HCC in segment 8 was associated with
the highest percentage of MVI when compared to all other
segments. The risk of MVI in segment 8 was 3.5-times
higher than the risk in other segments (p = 0.002) while no
vascular invasion was found in segment 1, 3, or 5. To evaluate
the association of the locoregional therapy with MVI, we
compared the treated lesions with radiofrequency ablation
and trans arterial chemo embolization to untreated HCC and
found that the risk of MVI in untreated HCC is 3 times the
risk in the treated HCC Odd ratio 3 and p=0.03.
4. Discussion
Liver cancers, which are predominately hepatocellular car-
cinoma, have high mortality rates and have been recently
Journal of Cancer Epidemiology 3
Table 2: Odds ratios of microvascular invasion.
Characteristics Microvascular Invasion Odds Ratio p-value
Single 10 1.5 0.3
Multifocal 6 0.6 0.3
Right Side 11 1.2 0.7
Left Side 2 0.6 0.3
Multiple Lobes 3 1.2 0.7
Single Lobe
Segment 1 0 0 0
Segment 2 1 1.7 1
Segment 3 0 0 0
Segment 4 1 1.3 0.7
Segment 5 0 0 0
Segment 6 2 2.0 0.19
Segment 7 0 0 0
Segment 8 6 3.5 0.002
Disease Etiology
HCV 8 1 1
EtOH 3 0.7 0.5
NASH 3 2.4 0.2
Tumor Size
Size > 2cm 10 0.4 0.6
Size < 2cm 6 1.2 0.6
Untreated 10 3.0 0.03
Treated 6 0.3 0.03
ranked as the second highest cancer-related death after lung
cancer with a rising incidence in the last decade based on
reports from the National Cancer Institute (NCI) [11, 12].
Treatment options for HCC depend mainly on two factors:
the characteristic of the tumor in regard to size, number,
and presence of vascular involvement and metastasis as well
as the severity of the underlying liver disease and function
as defined by the presence of portal hypertension and the
general functional status of the patient. According to the
American Cancer Society, the survival rates in patients with
HCC using the TNM system depend on the stage of the dis-
ease. High 5-years survival rates (31%) were associated with
localized cancer while low 5-year survival rates (3%) were
associated with distant metastasis [13]. Expectedly, untreated
HCC has a poor prognosis as defined by Giannini et al. who
studied 600 patients with untreated HCC and found the 5-
year survival to be 9.1%with amedian survival duration in the
advanced stages to be ranged between 6 and 7 months [14].
Surgical resection or liver transplantation remains corner-
stones of therapy and despite the improvements in surgical
techniques and perioperative care, long-term prognosis after
surgical resection and transplantation remains unsatisfactory
as the 5-year recurrence rate in resected HCC is estimated to
be 70% after liver transplantation [15–17]. Given the ability to
treat the underlying liver disease as well as the malignancy,
liver transplantation is the favored procedure over resection.
Identification of prognostic factors after potentially cura-
tive resection or transplant has been evaluated to iden-
tify patients at greatest risk for recurrence of HCC. On
multivariate analyses, the presence of microvascular metas-
tasis has been identified as the strongest individual predictor
of recurrence and survival in HCC patients [2]. In contrast
to macroscopic vascular invasion, which is detectable with
various imaging techniques and included as a diagnostic
parameter in many HCC scoring systems, MVI is difficult to
detect in the preoperative setting [18]. However, recent stud-
ies have supported its prognostic value in predicting risk of
tumor recurrence and survival following potentially curative
resection or transplant for HCC [8, 19–22]. Efforts to detect
MVI status in the preoperative setting as a means to guide
treatment have been attemptedwith diffusionweighted imag-
ing (DWI), gadoxetic acid-enhanced magnetic resonance
imaging (MRI), and 18F-fludeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) [23,
24]. Reliable applications of these approaches have yet to be
validated.
Multiple reviews have been conducted in an effort to
identify the prevalence of MVI and to correlate MVI with
tumor characteristics; however the results have been widely
variable and conflicting. A systematic review by Zhang et
al. found that the prevalence of MVI ranged widely from
15 to 57.1% [6]. Such a discrepancy can be explained by
geographical variations and a lack of consensus regarding
the definition of MVI [6]. They concluded that multinodular
disease, HCC tumor size >4 centimeters (cm), and lymph
node positivity were frequently associated with an increased
risk of MVI [23]. Conversely, Jackhete et al. found that MVI
was not associated with multilobar involvement in HCC,
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alpha fetoprotein (AFP) level, or the tumor differentiation
[25] while Haung et al. found in a large cohort study that
theMVIwas associated with AFP>200, tumor encapsulation,
tumor differentiation, and tumor size (>5cm) but no asso-
ciation was found with the gender, age, or etiology of the
cirrhosis [26]. Our cohort supports Haung’s findings as our
study showed no association between MVI with the etiology
of the cirrhosis, gender, or age. Our study did not show any
association between the MVI and multilobar HCC. Upon
comparing smaller tumor size (<2 cm) with larger tumor
size (>=2 cm), our data showed that there is no association
between theMVI and the size of the lesion, which contradicts
Haung’s result. This may be explained by a difference average
tumor size as our cohort included only transplanted patients
who, by Milan criteria, should have a tumor size less than 5
to be considered for liver transplantation.
As the prognostic value of preoperative identification
of MVI has been clearly stated, we attempted to define
a predictive relationship between the Couinaud segment
localization of HCC and the subsequent risk for MVI. Of the
98 explanted livers evaluated forHCC, 16 (16%)were found to
demonstrate MVI which is consistent with historical series.
Stratifying by Couinaud segments, HCC tumors involving
Couinaud segments 1, 3, 5, and 7 exclusively were not
associated with any risk of MVI. Despite the small average
size HCC in segment 8 (2.3cm), we found that it is a highly
associated with the risk of MVI (OR 3.5, p=0.002). We
found that the risk of MVI in segment 8 is three times
the risk compared with other segments. Lesions located in
segments 4, 5, and 8 are traditionally known as central HCC
[27]. The unique anatomical characteristic of the central
HCC’s location, adjacent to the main hepatic artery vascular
structure and having a dual blood supply from both left and
right hepatic arteries, carries an increased risk of MVI [28].
Given that our data showedno correlation ofMVIwith tumor
size and the overall smaller size of the lesions in segment
8, this supports an anatomical model for the increased risk
of MVI in segment 8. Of note, a limitation of our study is
that differences in tumor biology between segments were not
compared and thus potentially more aggressive lesions in
segment 8 may affect this model.
As mentioned above, one of the important predictors
of recurrence is the presence of MVI and studies showed
treating HCC with adjuvant therapy like TACE or RFA in
addition to surgical resection extends patient survival [29].
Our data shows that locoregional therapy to HCC decreases
the risk of MVI in the explanted livers and hypothetically
decreases the risk of recurrence. The benefit of locoregional
therapy, especially TACE, is debatable as Livoet et al. showed
an increased survival rate in unresectable HCC when com-
pared to the radical therapy while Oliveri et al. in his meta-
analysis showed that there is no benefit of TACE or trans
arterial embolization in unresectable HCC [30, 31]. Despite
the average size of the HCC tumors in our cohort being
relatively small, the locoregional therapy group showed a
decrease in the risk of MVI in the explanted liver. The risk
of MVI in untreated HCC is three time the risk in treated
HCC, thus suggesting that even smaller sized lesions may still
have MVI and may benefit from locoregional therapy either
neoadjuvant or adjuvantly as it has been shown to decrease
the risk of MVI.
5. Conclusion
Our data indicate that the risk of microvascular invasion is
highest in HCC tumors located in Couinaud segment 8. The
size and the number of HCC tumors were not associated with
an increased risk of microvascular invasion in our series of
patients. Locoregional therapy whether alone, adjuvant, or a
bridge to transplantation can decrease the risk of MVI. We
recommend a larger and prospective study to investigate the
effect of the locoregional therapy in decreasing the risk of
MVI.
Data Availability
The data for this research was provided by the University of
Massachusetts Medical Center.
Additional Points
Limitations. Our study has the limitations inherent to a
retrospective review of data, and a selection bias cannot be
excluded because we included only transplanted patients.
While all data were recorded prospectively and in real-time,
there was no treatment or intervention arm, thus direct cause
and effect conclusions cannot be drawn. Comparison of our
data to historical series is limited given the heterogeneity
of study populations and lack of consistency in anatomic
definitions of MVI. Further randomized controlled trials
are needed in the future to more thoroughly address these
questions.
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